INTERLEUKIN-6 RECEPTOR INHIBITORS IN THE MANAGEMENT OF PATIENTS WITH SEVERE SARS-COV-2 PNEUMONIA
- Funded by Lundbeck Foundation
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
2020Known Financial Commitments (USD)
$587,850Funder
Lundbeck FoundationResearch Location
DenmarkLead Research Institution
Bispebjerg HospitalResearch Priority Alignment
N/A
Research Category
Clinical characterisation and managementResearch Subcategory
Clinical trials for disease managementSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
Randomized Controlled TrialBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
Data from China indicate that a known anti-rheumatism drug may have an inhibitory effect on the inflammation that damages patients' lungs when they contract COVID-19. In a controlled, randomised trial, the researchers at Bispebjerg Hospital will investigate whether the assumptions about the beneficial effect of this drug hold water.